Eli Lilly Wins Cancer Drug Patent Case at U.K. Supreme Court
- Judges uphold patents covering third-best selling drug Alimta
- Products by Actavis infringe patents on cancer treatment
Leukemia cells
Soruce: Smith Collection/Gado/Getty ImagesThis article is for subscribers only.
Eli Lilly & Co. won a patent dispute with Actavis at the U.K.’s top court, marking a victory in a long-running legal campaign to defend its third best-selling drug, Alimta, from rival products.
The London-based Supreme Court found that Actavis products infringe Lilly patents in the U.K., France, Italy and Spain, a spokesman said. The judges will release a full decision on Wednesday. Allergan Plc sold the Actavis business unit to Teva Pharmaceutical Industries Ltd. last year, a spokeswoman said.